Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Pioglitazone in Impaired Glucose Tolerance
- Conditions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 120
- Registration Number
- NCT00306826
- Locations
- 🇩🇪
Praxis Gunter Kässner, Leipzig, Germany
🇩🇪Praxis Matthias Weissbrodt, Leipzig, Germany
🇩🇪Praxis Matthias Schreiner, Leipzig, Germany
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
- Conditions
- Interventions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 38
- Registration Number
- NCT00300365
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 565
- Registration Number
- NCT00295633
- Locations
- 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸Mouhaffel, Assad H., West Monroe, Louisiana, United States
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 400
- Registration Number
- NCT00290940
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 493
- Registration Number
- NCT00286494
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2006-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00280865
- Locations
- 🇲🇽
Research Site, Delegacion Cuauhtemoc, Mexico
Role of Pioglitazone in Preventing Diabetes
- Conditions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- M.V. Hospital for Diabetes
- Registration Number
- NCT00276497
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00269061
- Locations
- 🇺🇸
GSK Investigational Site, Belmont, Massachusetts, United States
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 56
- Registration Number
- NCT00231894
- Locations
- 🇺🇸
Nathan Kline Institute for Psychiatric Research, New York, New York, United States
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT00232583
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.